AKT1 and prostate carcinoma: Similarly, on the basis of the finding that FGFR signaling is overactivated in advanced prostate cancer, the combined use of AZD4547 (FGFR receptor kinase inhibitor) and AZD5363 (Akt inhibitor) has led to a reduction in the proliferation of prostate cancer cells both in vitro and in vivo [161].